Aug 2026· Tumour Virus Research· Vol 22, pp. 200349· 0 citations· 48 references
Medicine
TL;DR
Ex vivo data mining allowed us to integrate ex vivo clinical and immunological data, revealing a central role for CD8+CD25+ cells in ATL survival and HIT-BAY might serve as a prototype to model immune response and facilitate biomarker and therapeutic target discovery in real-world cohorts, including rare malignancies.
Abstract
Adult T-cell leukemia (ATL) is a rare but aggressive CD4+CD25+ leukemia triggered by HTLV-1 infection. We quantified ex vivo levels of CD4+ and CD8+ (sub)populations and their antiproliferative, pro-apoptotic, antiviral and immunomodulatory interplay in short-term culture of primary cells from ATL patients, in a long-term prospective study (819 person-years of follow-up). We integrated clinical, cellular and molecular data into a data mining approach combining linear (consensus HIerarchical Tree clustering) and non-linear (BAYesian network) models. This HIT-BAY approach revealed an association between CD8+CD25+ cells and survival, independent of CD4+CD25+ cells. Moreover, CD8+CD25+ levels at diagnosis significantly predicted 5-year survival in ATL patients (p = 0.037), which was confirmed in multivariable Cox regression models correcting for clinical forms. We provide in vivo support for our ex vivo model in a unique patient on AZT monotherapy, for whom adding IFN-α resulted in a rapid (<2 weeks) and pronounced (>70%) decline in leukemic/non-leukemic cell ratio, accompanied by a ten-fold increase CD8+CD25+ levels, and followed by long-term survival. Finally, transcriptomic analysis of a CD8+CD25+ gene module and replication in an independent ATL cohort revealed shared cytotoxic activity of both CD8+CD25+ and Tax-specific CD8+ cells as an underlying mechanism for prolonged survival. In conclusion, our integrated data mining approach allowed us to integrate ex vivo clinical and immunological data, revealing a central role for CD8+CD25+ cells in ATL survival. HIT-BAY might serve as a prototype to model immune response and facilitate biomarker and therapeutic target discovery in real-world cohorts, including rare malignancies.
Background T-cell function is regulated by immunometabolism, and lysosomes are signaling hubs. CD68 (LAMP4), traditionally regarded as a monocyte/macrophage marker, has been largely neglected in T cell biology. We aimed to assess the link between CD68 expression in T cells and anti-PD-1 response in lung cancer, and its...
Ying Wang, Jing Huang, Zheng-Yi Sun et al.· Frontiers in Immunology· 0 citations
Compared with CD19 CAR-T therapy, CD7 CAR-T therapy was characterized by reduced CD8+ CAR-T persistence, early exhaustion, and delayed immune reconstitution, correlating with increased infections and higher non-relapse mortality.
Zhi-Peng Zhou, Yi-Yang Ding, Zhuo-Jun Liu et al.· Journal of Translational Int...· 0 citations
CD38+HLA-DR+CD8+ T cells are identified as a potential mechanistic link between Still's disease and MAS and highlight this subset as a candidate therapeutic target.
Greta Rogani, R. Erkens, A. Bodelón et al.· Arthritis & Rheumatology· 0 citations
Bispecific antibodies (BsAbs) targeting CD20 × CD3 have achieved remarkable efficacy in relapsed or refractory (R/R) B-cell lymphoma, yet clinical responses remain heterogeneous and predictive biomarkers are lacking. We retrospectively evaluated associations between peripheral immune profiles and outcomes in 40 patient...
Hui Yu, Jin Chai, Jiao-Wu Cao et al.· Hematological Oncology· 0 citations
Immune dysregulation is central to acute myeloid leukemia (AML), but the contribution of specific immune subsets remains uncertain. We combined Mendelian randomization (MR), clinical flow cytometry, and transcriptomic profiling to investigate HLA-DR+ CD8+ T cells in AML. Two-sample MR using 731 immunophenotypes and AML...
Gang Chen, Jing Xu, Xiao-Yu He et al.· Clinical Immunology· 0 citations
Background T cells play a central role in antitumor immunity. Emerging evidence indicates that T-cell plasticity and differentiation states are associated with clinical outcomes and responses to cancer immunotherapy. CD8⁺ T cells that retain differentiation potential are thought to sustain effective antitumor immunity....
Le Xing, Dan He, Dong-Mei Li et al.· ImmunoTargets and Therapy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.